BeiGene's H1 Loss Narrows as Revenue Rises
BeiGene's (HKG:6160, SHA:688235) loss narrowed to $371.6 million in the first half from $729.6 million in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
Loss per share at the drug company halved to $0.27 from $0.54 a year earlier. Analysts polled by Visible Alpha expected a loss per share of $0.01.
Revenue grew to $1.68 billion from $1.04 billion the previous year. The Visible Alpha consensus forecast was $928.5 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.